G0433

Infectious agent antigen detection by enzyme immunoassay (EIA) technique, HIV-1 and/or HIV-2, screening

The Healthcare Common Procedure Coding System (HCPCS) code G0433 describes a laboratory test performed to screen for the presence of the Human Immunodeficiency Virus (HIV), specifically types 1 and/or 2, using an enzyme immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA) technique. This test is primarily utilized for the preventative screening of asymptomatic individuals to identify early stages of HIV infection, enabling timely medical intervention and reducing the risk of transmission. The EIA/ELISA methodology involves detecting HIV-specific antigens and/or antibodies in a patient serum or plasma sample. During the assay, the patient sample is incubated with HIV antigens or antibodies bound to a solid phase, such as a microtiter plate. If HIV antibodies or antigens are present in the sample, they bind to the specific targets. Following a series of washing steps to remove unbound materials, an enzyme conjugate is added, which binds to the antigen-antibody complexes. A substrate is then introduced, reacting with the enzyme to produce a measurable color change. The intensity of this color is quantified spectrophotometrically and is proportional to the amount of HIV antigen or antibody in the sample. This highly sensitive and specific screening tool is critical in public health and preventative care. Code G0433 is typically utilized for Medicare beneficiaries in alignment with specific coverage determinations, which allow for annual screening of individuals at increased risk for HIV infection, screening of pregnant women, and routine screening for individuals between the ages of 15 and 65. If the initial EIA/ELISA test is reactive (positive), standard clinical protocols require a confirmatory supplementary test, such as a Western blot or a more specific HIV-1/HIV-2 differentiation assay, to definitively diagnose the infection. This screening test represents a foundational element of public health strategies aiming to reduce the transmission of HIV through early detection, allowing for immediate counseling, linkage to care, and the initiation of antiretroviral therapy (ART) which can effectively suppress the viral load to undetectable levels, thereby preventing further transmission.

Clinical Indications

  • Routine preventative screening for asymptomatic individuals aged 15 to 65 years.
  • Annual screening for individuals determined to be at increased risk for HIV infection, including those with a history of sexually transmitted infections, injection drug use, or high-risk sexual behavior.
  • Screening for pregnant women during their first prenatal visit to prevent perinatal transmission.
  • Additional screening for pregnant women at high risk for HIV during the third trimester.
  • Screening following potential occupational or non-occupational exposure to HIV as part of a post-exposure prophylaxis protocol.

Procedure Steps

  1. Collect a venous blood sample from the patient via venipuncture into an appropriate collection tube.
  2. Centrifuge the collected blood sample in the laboratory to separate the serum or plasma from the cellular components.
  3. Prepare the EIA/ELISA microtiter plate, which is pre-coated with specific HIV-1 and/or HIV-2 antigens or antibodies.
  4. Dispense a specified and precise volume of the patient serum or plasma into the designated test wells of the microtiter plate.
  5. Incubate the microtiter plate at the required temperature for a specified duration to allow any HIV antibodies or antigens present in the sample to bind to the coated targets.
  6. Wash the microtiter plate thoroughly using a specialized buffer solution to remove any unbound serum proteins and extraneous materials.
  7. Add an enzyme-linked conjugate solution to the wells, which binds to the captured HIV antigen-antibody complexes, and incubate again.
  8. Perform a second wash cycle to remove any unbound enzyme conjugate from the wells.
  9. Add a chromogenic substrate solution to the wells and incubate, allowing the enzyme to catalyze a chemical reaction that produces a visible color change.
  10. Add a stopping solution (such as a dilute acid) to halt the enzymatic reaction.
  11. Read the optical density (absorbance) of the wells using a microplate spectrophotometer to determine the reactivity of the sample.
  12. Interpret the spectrophotometric results based on the manufacturer established cutoff values and report the findings as either non-reactive or reactive.

Coding Guidelines

  • Use G0433 exclusively for preventative screening purposes; do not use for diagnostic testing of a patient presenting with symptoms of HIV.
  • For diagnostic HIV testing, refer to the appropriate CPT codes (e.g., 87389) rather than HCPCS screening codes.
  • Medicare covers one annual voluntary HIV screening for beneficiaries at increased risk, and a maximum of three voluntary HIV screenings for pregnant Medicare beneficiaries per term.
  • If the screening test is performed using a CLIA-waived test kit in an approved setting, append modifier QW to G0433 to indicate a waived test.
  • Ensure the appropriate primary screening diagnosis code (e.g., Z11.4) is reported to substantiate the medical necessity of the preventative encounter.
  • Do not report G0433 in conjunction with other HIV screening or diagnostic codes for the same encounter unless clinically justified, supported by distinct methodologies, and utilizing separate samples.

Associated ICD-10 Codes